Patients with gliomas harbouring IDH1 or IDH2 mutations have been shown to have a decreased risk of thromboembolism, which may be related to a decreased expression of tissue factor, leading to a decrease in coagulation system activation [14,15]. The gene discussed is IDH2; the disease is central nervous system cancer.